Switch theme
Sign up to access all valuation multiples
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
1994
1.1K+
LTM Revenue $2.2B
LTM EBITDA $743M
$10.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Exelixis has a last 12-month revenue (LTM) of $2.2B and a last 12-month EBITDA of $743M.
In the most recent fiscal year, Exelixis achieved revenue of $2.2B and an EBITDA of $719M.
Exelixis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Exelixis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Profit | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | $743M | XXX | $719M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $673M | XXX | $690M | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $576M | XXX | $521M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Exelixis's stock price is $43.
Exelixis has current market cap of $11.7B, and EV of $10.9B.
See Exelixis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.9B | $11.7B | XXX | XXX | XXX | XXX | $2.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Exelixis has market cap of $11.7B and EV of $10.9B.
Exelixis's trades at 5.0x EV/Revenue multiple, and 15.2x EV/EBITDA.
Equity research analysts estimate Exelixis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Exelixis has a P/E ratio of 20.4x.
See valuation multiples for Exelixis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.7B | XXX | $11.7B | XXX | XXX | XXX |
| EV (current) | $10.9B | XXX | $10.9B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 15.2x | XXX | XXX | XXX |
| EV/EBIT | 16.2x | XXX | 15.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.4x | XXX | 22.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 17.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialExelixis's last 12 month revenue growth is 9%
Exelixis's revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $1.2M for the same period.
Exelixis's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Exelixis's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Exelixis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 103% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Exelixis acquired XXX companies to date.
Last acquisition by Exelixis was XXXXXXXX, XXXXX XXXXX XXXXXX . Exelixis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Exelixis founded? | Exelixis was founded in 1994. |
| Where is Exelixis headquartered? | Exelixis is headquartered in United States of America. |
| How many employees does Exelixis have? | As of today, Exelixis has 1.1K+ employees. |
| Who is the CEO of Exelixis? | Exelixis's CEO is Dr. Michael M. Morrissey, PhD. |
| Is Exelixis publicy listed? | Yes, Exelixis is a public company listed on NAS. |
| What is the stock symbol of Exelixis? | Exelixis trades under EXEL ticker. |
| When did Exelixis go public? | Exelixis went public in 2000. |
| Who are competitors of Exelixis? | Similar companies to Exelixis include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Exelixis? | Exelixis's current market cap is $11.7B |
| What is the current revenue of Exelixis? | Exelixis's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Exelixis? | Exelixis revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Exelixis? | Current revenue multiple of Exelixis is 4.9x. |
| Is Exelixis profitable? | Yes, Exelixis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Exelixis? | Exelixis's last 12 months EBITDA is $743M. |
| What is Exelixis's EBITDA margin? | Exelixis's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Exelixis? | Current EBITDA multiple of Exelixis is 14.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
